source
- FDA briefing hints tough road for Capricor and Replimune ahead of advisory committee meetingsThe FDA released briefing documents for upcoming advisory committee meetings concerning Capricor Therapeutics' Duchenne muscular dystrophy cell therapy and Replimune's advanced melanoma candidate.…
- Latigo's mid-stage trial shows non-opioid pill LTG-001 cuts post-surgery pain, outperforms placeboLatigo Biotherapeutics reported positive Phase 2 data for its experimental oral analgesic LTG-001, tested in patients who had undergone tummy-tuck surgery. The study enrolled 343 participants who w…